Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.

Vaccine
Ann ThanawastienKevin P Killeen

Abstract

Pneumolysin is a highly conserved, cholesterol-dependent cytolysin that is an important Streptococcus pneumoniae virulence factor and an attractive target for vaccine development. To attenuate pneumolysin toxicity, a genetic toxoid was constructed with two amino acid changes, G293S and L460D, termed PLY-D, that reduced cytolytic activity > 125,000-fold. In mice, PLY-D elicited high anti-PLY IgG antibody titers that neutralized the cytolytic activity of the wild-type toxin in vitro. To evaluate the protective efficacy of PLY-D, mice were immunized intramuscularly and then challenged intranasally with a lethal dose of 28 clinical isolates of S. pneumoniae originating from different geographical locations, disease states (i.e. bacteremia, pneumonia), or body sites (i.e. sputum, blood). PLY-D immunization conferred significant protection from challenge with 17 of 20 serotypes (85%) and 22 of 28 strains (79%). Further, we demonstrated that immunization with PLY-D provided statistically significant improvement in survival against challenge with serotype 4 and 18C strains compared to mice immunized with a pneumococcal conjugate vaccine Prevnar 13® (PCV13). Co-administration of PLY-D and PCV13 conferred greater protection against chall...Continue Reading

References

Feb 1, 1987·Journal of Clinical Microbiology·K Kanclerski, R Möllby
Feb 6, 1998·The Journal of Laboratory and Clinical Medicine·J B Rubins, E N Janoff
Jan 23, 1999·Journal of Immunological Methods·A FreyD Zurakowski
Jan 23, 1999·Microbial Pathogenesis·J B RubinsE N Janoff
Oct 23, 2004·Clinical and Experimental Immunology·R A HirstP W Andrew
Jan 30, 2007·Respiratory Research·María Del Mar García-SuárezFrancisco J Méndez
Apr 7, 2007·The Journal of Biological Chemistry·Casie E SoltaniRodney K Tweten
Feb 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Allison J FarrandRodney K Tweten
Mar 15, 2011·Vaccine·Susan S HuangJonathan A Finkelstein
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
Jul 3, 2013·Cold Spring Harbor Perspectives in Medicine·Birgitta Henriques-Normark, Elaine I Tuomanen
May 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shamez N Ladhani, Mary E Ramsay

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.